NCT05185154

Brief Summary

The aim of this prospective study is to evaluate the natural course and prognosis of hospitalized patients with liver cirrhosis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
336

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2021

Longer than P75 for all trials

Geographic Reach
1 country

4 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2021

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 20, 2021

Completed
22 days until next milestone

First Posted

Study publicly available on registry

January 11, 2022

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2023

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2025

Completed
Last Updated

January 11, 2022

Status Verified

January 1, 2022

Enrollment Period

2 years

First QC Date

December 20, 2021

Last Update Submit

January 6, 2022

Conditions

Liver Cirrhosis

Outcome Measures

Primary Outcomes (2)

  • All-cause mortality

    Death from any cause

    Up to 2 years

  • Liver-related mortality

    Death from liver disease

    Up to 2 years

Secondary Outcomes (1)

  • Cause of admission to hospital

    At baseline

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Hospitalized patients with liver cirrhosis

You may qualify if:

  • Hospitalized patients with liver cirrhosis
  • Admission to the hospital because of cirrhotic complications such as uncontrolled ascites, variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis, hepatocellular carcinoma, acute kidney injury, bacterial infection, acute liver failure, and etc.

You may not qualify if:

  • Admission to the hospital without cirrhotic complications
  • Patients who refuse the follow-up of outpatient department

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Hallym University Dongtan Sacred Heart Hospital

Hwaseong-si, South Korea

RECRUITING

Chosun University Hospital

Kwangju, South Korea

RECRUITING

Jae Yoon Jeong

Seoul, South Korea

NOT YET RECRUITING

Kangbuk Samsung Hospital

Seoul, South Korea

NOT YET RECRUITING

MeSH Terms

Conditions

Liver Cirrhosis

Condition Hierarchy (Ancestors)

Liver DiseasesDigestive System DiseasesFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Won Sohn, MD, PhD

    Kangbuk Samsung Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Won Sohn, MD, PhD

CONTACT

82-2-2001-2557hand0827@naver.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
2 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 20, 2021

First Posted

January 11, 2022

Study Start

November 1, 2021

Primary Completion

October 31, 2023

Study Completion

October 31, 2025

Last Updated

January 11, 2022

Record last verified: 2022-01

Locations

KR(4)